GYNEZOL
The computed 12-month bankruptcy probability of GYNEZOL is 0.3% (very low). The 2024 annual accounts show equity of €6k. Its solvency ranks better than 10% of 383 sector peers (fiscal year 2024). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €6k |
| Staff (FTE) | 2 |
| Better than sector | 10% |
| Active | 2 yrs |
This figure rests on 3 of 5 axes. Too few to say where this company is strong or weak.
Computed on 3 of 5 axes. Not measured: profitability, growth. An unmeasured axis is not a zero: no data was read for it.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 0.2% | 50.4% | |
| Equity | €6k | €128k | |
| Gross operating margin | €37k | €180k | |
| Staff costs | €34k | €135k | |
| Total assets | €2.32M | €552k |
| Fiscal year | 2024 |
|---|---|
| Deposit | verkort |
| Revenue | - |
| EBITDA | €3k |
| Net profit | - |
| Cash flow | - |
| Staff costs | €34k |
| Income taxes | - |
| Dividends | - |
| Total assets | €2.32M |
| Equity | €6k |
| Debt | €2.32M |
| of which ≤ 1y | €187k |
| of which > 1y | - |
| Working capital | €2.12M |
| Employees (FTE) | 2.0 |
| 2024 | |
|---|---|
| Current ratio | 12.36 |
| Quick ratio | 12.36 |
| Working capital ratio | 91.4% |
| Solvency | 0.2% |
| Debt / equity | 421.45 |
| Long-term debt ratio | - |
| Interest coverage | 4.90 |
| Gross margin | - |
| Net margin | - |
| ROA | - |
| ROE | - |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (16 line items)
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €2.32M |
| Fixed assets | 21/28 | €12k |
| Tangible fixed assets | 22/27 | €12k |
| Current assets | 29/58 | €2.31M |
| Amounts receivable within one year | 40/41 | €6k |
| Cash & bank | 54/58 | €46k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €2.32M |
| Equity | 10/15 | €6k |
| Contributions / capital | 10/11 | €6k |
| Amounts payable | 17/49 | €2.32M |
| Amounts payable within one year | 42/48 | €187k |
| Trade debts payable within one year | 44 | €20k |
| Income statement | ||
| Gross operating margin | 9900 | €37k |
| Operating result | 9901 | €613 |
| Financial income | 75 | €0 |
| Financial charges | 65 | €613 |
| NACE primary | Activiteiten van medisch specialisten(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 23-04-2024 |
| Status | Active |
| Postal code | 3600 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71016I1216/00S000 | Flanders | 16.0 ha | 1 · 3.6 ha | - |
| 71011I1143/00F000 | Flanders | 2,288 m² | 1 · 339 m² | 11.3 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
| Legal nameNL | GYNEZOL |